Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata
We are so excited to announce that yesterday the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for CoNCERT Pharmaceuticals'